期刊文献+

adeABC基因对鲍氏不动杆菌耐药性的影响 被引量:8

Effects of adeABC gene expression on drug resistance of Acinetobacter baumannii
下载PDF
导出
摘要 目的探讨临床分离鲍氏不动杆菌adeABC基因的表达及其对鲍氏不动杆菌耐药性的作用。方法采用E-test法对临床分离的鲍氏不动杆菌进行耐药性检测,逆转录聚合酶链反应(RT-PCR)检测adeABC基因的表达。结果鲍氏不动杆菌对不同抗菌药物的耐药率如下:哌拉西林97.6%,头孢吡肟60.8%,头孢噻肟75.2%,头孢他啶75.2%,环丙沙星80.0%,左氧氟沙星79.2%,阿米卡星60.8%,庆大霉素50.4%,亚胺培南35.2%,多黏菌素B0.0%,哌拉西林/他唑巴坦48.8%。多重耐药鲍氏不动杆菌的adeB基因携带率为95.0%,调控基因adeR、adeS携带率分别为90%、90%;敏感株的adeB基因携带率为58.1%,调控基因adeR、adeS携带率分别为49.5%、50.4%。结论 adeABC基因表达增强是鲍氏不动杆菌产生耐药性的重要机制。 Objective To discuss adeABC gene expression in clinically separated Acinetobacter baumannii and its effects on drug resistance of Acinetobacter baumannii.Methods E-test method was adopted to clinically separate Acinetobacter baumannii which was subjected to drug resistance testing.Reverse transcriptase-polymerase chain reaction(RT-PCR)was used to detect expression of adeABC gene.Results Drug resistance rates of Acinetobacter baumannii against different antibacterial agents were as follow:piperacillin 97.6%,cefepime 60.8%,cefotaxime 75.2%,ceftazidime 75.2%,ciprofloxacin 80.0%,levofloxacin 79.2%,amikacin 60.8%,gentamicin 50.4%,imipenem 35.2%,polymyxin B 0.0%,piperacillin/tazobactam 48.8%.Carrier rate of adeABC gene in multidrug-resistant Acinetobacter baumannii was 95.0% while those of regulatory gene adeR and adeS were 90%,90%,respectively.Carrier rate of adeB gene in sensitive strains was 58.1% while those of regulatory gene adeR and adeS were 49.5%,50.4%,respectively.Conclusion Enhancement of adeABC gene expression is an important mechanism of drug resistance of Acinetobacter baumannii.
出处 《国际检验医学杂志》 CAS 2013年第9期1069-1070,1073,共3页 International Journal of Laboratory Medicine
关键词 鲍氏不动杆菌 抗药性 细菌 基因表达 adeABC基因 acinetobacter baumannii drug resistance,bacterial gene expression abcABC gene
  • 相关文献

参考文献14

  • 1Peleg AY, Seifert H, Paterson DL. Aeinetobacter baumannii.. emergence of a successful pathogen[J]. Clin Microbiol Rev, 2008,21 (3) : 538-582.
  • 2Kemp{ M, Rolain JM. Emergence of resistance to earbapenems in Acinetobacter baumannii in Europe:clinical impact and therapeu tic options[J]. Int J Antimicrob Agents,2012,39(2) :105 114.
  • 3Kim BN, Peleg AY,Lodise TP, et al. Management of meningitis due to antibiotic-resistant Aeinetobacter species[J]. I.ance: Infect Dis,2009,9(4) :245-255.
  • 4Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria., an update[J]. Drugs,2009,69(12) :1555 1623.
  • 5Endo S, Yano H, Hirakata Y, et al. Molecular epidemiology of car bapenem-non susceptible Acinetobacter baumannii in Japan[J]. J Antimicrob Chemother,2012,67(7) :1623-1626.
  • 6Tayabali AF, Nguyen KC, Shwed PS, et al. Comparison of the viru lence potential of Acinetobacter strains from clinical and environ mental sources[J]. PLoS One, 2012,7 (5) : e37024.
  • 7Snellman EA, Sullivan ER, Colwell RR. Purification and proper ties of the extraeellular lipase, LipA,of Aeinetobacter sp. RAG-[J] Eur J Biochem,2002,269(23) :5771-5779.
  • 8Lin L,Ling BD,Li XZ. Distribution of the multidrug efflux pump genes,adeABC,adeDE and adelJK,and class l integron genes in multiple antimicrobial-resistant clinical isolates of Acinetobacter baumannii Acinetohaeter calcoaceticus complex [J].:lnt J Antimicrob Agents,2009,33(1) :27-32.
  • 9Fournier PE, Vallenet D,Barbe V, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii[J]. PLoS Genet, 2006,2(1) =eT.
  • 10Perez F, Hujer AM, Hujer KM, et al. Global Challenge of Multi- drug Resistant Acinetobacter baumannii[J]. Antimicrob Agents Chemother, 2007,51(10) =3471-3484.

同被引文献88

  • 1刘世旺,徐艳霞,郑永良.连翘乙醇提取物对细菌生长曲线的影响[J].安徽农业科学,2007,35(24):7383-7384. 被引量:18
  • 2吕吉云,曲芬.多重耐药微生物及防治对策[M].北京:人民军医出版社,2011:3.
  • 3HOU PF,CHEN XY, YAN GF, et al. Study of the correlation of imipenem resistance with efflux pumps AdeABC, AdeIJK, AdeDE and AheM in clinical isolates of Acinetobaeter baumannii[J].Chemother, 2012,58(2) : 152- 158.
  • 4RAJAMOHAN G, SRINIVASAN VB, GEBREYES WA. Molecular and functional characterization of a novel efflux pump, AmvA, mediating antimicrobial and disinfectant resistance in Acinetobacter baumannii [J]. J Antimicrob Chemother, 2010,65 (9) : 1919- 1925.
  • 5Zhao WH, Hu ZQ. Acinetobacter: a potential reservoir and dis- penser for 13-1actamases[ J]. Crit Rev Microbiol, 2012, 38 ( 1 ) : 30-51.
  • 6Peleg AY, Seifert H, Paterson DL. Acinetobacter baurnannii : emer- gence of a successful pathogen[ J]. Clin Microbiol Rev, 2008, 21 (3) : 538-582.
  • 7Golanbar GD, Lam CK, Chu YM, et al. Phenotypic and molecular characterization of Acinetobacter clinical isolates obtained from in- mates of California correctional facilities [ J ]. J Clin Microbiol, 2011, 49(6): 2121-2131.
  • 8de Breij A, Dijkshoorn L, Lagendijk E, et at. Do biofilm fmanation and interactions with human ceils explain the clinical success of Acinetobacter baumannii? [J]. PLoS One, 2010, 5(5) : e10732.
  • 9Vashist J, Tiwari V, Das R, et al. Analysis of penicillin-binding proteins( PBPs ) in carbapenem resistant Acinetobacter baumannii [J].IndianJMed Res, 2011, 133(3): 332.
  • 10Liu YH, Kuo SC, Lee YT, et al. Amino acid substitutions of quin- olone: resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acineto- batter genomic species 13TU [ J ]. J Microbiol Immunol Infect, 2012, 45(2): 108-112.

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部